NON-communicable diseases, RANDOMIZED controlled trials, DRUG efficacy, CLINICAL drug trials
Abstract
Fabrizio Faggiano and colleagues discuss how a central, transparent, and evidence-based approval process is needed for behavioral prevention interventions in Europe and propose a way forward. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]